Replies to post #207358 on Biotech Values

[realfast95]

$ELGX - Endologix resumes shipments, procedures with AFX, some sizes of AFX2 Endologix provided an update on the previously announced temporary hold on shipments of its AFX and AFX2 Endovascular AAA Systems. Based upon positive testing results, the company has removed the temporary hold on all sizes of the AFX Endovascular AAA System and some sizes of the AFX2 Endovascular AAA System, which will allow these products to be shipped to customers and used in procedures, effective immediately. Testing and process improvements for the remaining sizes of the AFX2 system are on-going.

Read more at:
http://thefly.com/landingPageNews.php?id=2482198

[Giovanni]

Can CTIX come back from the dead


BioTechMaven Member Profile BioTechMaven Monday, January 2, 2017 6:13:26 PM
Re: DaubersUP post# 167154 Post #
167157
of 167160 Go
Essentially, 4 months away to learning if Prurisol is better than Otezla, a forecasted $2 Billion dollar drug in 2017. If you believe the small sample size of the 200mg arm in the Phase 2 trial, Prurisol has already bettered Otezla. The proof will be in the pudding and the fascinating thing is it's coming up on us very soon. I'm also watching the Brilacidin trial for UP/UC very closely. It's a tremendously huge market and it will be fascinating to see the final report for this trial. Lastly, hopeful that the Kevetrin engine fires back up into the start of its Phase 2. Three drugs, three hugely lucrative markets, chips scattered across the table. I'll be looking to add big chunks within the next 90 days, and average down a bit. Will hold majority through first partnership announcement (I'm assuming summer or fall '17), though a sharky big pharma could sneak in any time and acquire one or two drugs, or the entire company. You don't make it to Phase 2 with three drugs and not have one of them attract a suitor--not possible. Just a matter of time. I'm continuing to weight Prurisol as the heaviest near term catalyst and maintaining a valuation of $5-10B if the trial delivers anything north of 30 % at PASI 75, which I firmly believe it can and will. big pharma won't underpay Cellceutix after a stellar 2B completion, that's the sweet spot for big deal making.